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Analysis of antithrombotic therapy in patients over 75 years with non-
valvular atrial fibrillation: do we apply the guidelines to elderly subjects?
Camelia Sorea, Frédéric Georger, Rafi Makhoul
Centre Hospitalier de Béziers, Cardiologie, Béziers, France
Introduction and Objectives: Atrial fibrillation (AF) is associated with a
five times higher risk of stroke mortality. The benefit of anticoagulants in this
context is widely recognized, particularly for older patients. Past studies show
reluctance to anticoagulate seniors because of their bleeding risk. The Euro-
pean guidelines are regularly updated to promote the prescription of anti-
coagulants in this population. The purpose of this study is to evaluate the type
and rate of antithrombotic prescription in real life in patients over 75 years
with a history of non-valvular AF.
Methods: This is a retrospective study performed in Nimes University
Hospital and Béziers Hospital. We studied 293 consecutive outpatients who
consulted their cardiologist between April and November 2012. The following
data were analyzed: CHA2DS2VASc score, HAS-BLED score, antithrombotic
therapy, type of AF, demographics.
Results: The mean age of patients is 82 years (+/-5.1 years, 75-99 years).
219 patients (74.7%) receive oral anticoagulants: 60.4% are treated with
vitamin K antagonists (VKA) and 14.3% with novel oral anticoagulants
(NOACs). 60 patients (20.6%) get aspirin or clopidogrel alone or in
various combinations, 14 patients (4.7%) receive no antithrombotic treatment.
The rate of anticoagulation (VKA or NOACs) decrease moderately with age:
81.5% (75-79 years), 75% (80-84 years) and 67% after 85 years. It is more
important in case of permanent AF (83%) versus paroxysmal (67%). Women
are less anticoagulated (67%) than men (82%).
Conclusions: A higher rate of anticoagulation is found in this elderly pop-
ulation compared with previous “real life” records. Anticoagulant therapy is
however less systematic in paroxysmal AF and women.
0382
AMPKalpha1 regulates actin polymerization, lamellipodia formation
and clot retraction, in thrombin-stimulated platelets
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Background: Platelet activation requires sweeping morphological
changes, supported by contraction and remodelling of platelet actin cytoskel-
eton. In epithelial and endothelial cells, AMP-activated protein kinase
(AMPK) controls actin cytoskeleton organization through the phorphorylation
of cytoskeletal targets, namely myosin regulatory light chains (MLC), cofilin
and the vasodilator-stimulated phosphoprotein (VASP), extending the role of
AMPK beyond metabolism.
Objectives: in this study, we hypothesized that AMPK was activated in
thrombin-stimulated platelets and played a role in platelet secretion, aggrega-
tion and clot retraction, by regulating polymerization and/or organization of
actin cytoskeleton through the phosphorylation of MLC, cofilin and VASP.
Results: Human platelets expressed exclusively the AMPKalpha1 isoform.
In human purified platelets, thrombin led to a transient activation of
AMPKalpha1 and to phosphorylation of its bona fide substrate, acetyl coA
carboxylase (ACC). Platelets isolated from mice lacking AMPKalpha1 exhib-
ited reduced aggregation and secretion response to thrombin, associated with
a defect in ACC, MLC, cofilin and VASP phosphorylation. These changes
were associated with an abrogration of thrombin-dependent F-actin formation.
Moreover, the percentage of platelets able to form lamellipodia after immobi-
lization on fibrinogen-coated coverslips and stimulation by thrombin, was sig-
nificantly reduced in the absence of AMPKalpha1, indicating an altered
cytoskeleton reorganization during spreading. More importantly, clot retrac-
tion was slower and less effective in KO platelets.
Conclusions: AMPKalpha1 plays a critical role in platelet function in
response to thrombin through the phrophorylation of cytoskeletal targets and
the subsequent regulation of cytoskeleton organization-dependent processes.
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Impaired P2Y12 inhibition by clopidogrel in patients with kidney
transplantation
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Introduction: Several studies have indicated that impaired GFR is an
important predictor factor associated with impaired platelet inhibition by clop-
idogrel. In chronic kidney disease, the presence of low platelet inhibition by
clopidogrel is associated with adverse outcome following PCI and stenting. In
the present study, we sought to determine if renal transplantation per se alters
clopidogrel pharmacodynamics.
Patients and methods: 36 patients with kidney transplantation were
enrolled in one single center (Nephrology Department, Hôpitaux Universita-
ires de Strasbourg). Control patients were 126 patients with different degrees
of chronic renal failure, tested in the same conditions. Inclusion criteria were
patients under clopidogrel treatment of 75mg per day for at least 8 days.
Unstable patients or those presenting with any conditions that could account
for reduced platelet inhibition by clopidogrel (heart failure, shock) were
excluded. Treatment and medical history were collected at inclusion. Clopido-
grel pharmacodynamics was studied using the VASP assay.
Results: Patients with kidney transplantation were younger (58.3 vs
72.6 years, p<0.001), less likely diabetics (39% vs 57%, p=0.12), presented a
lower BMI (25.2 sv 27.2 p=0,05), the estimated glomerular filtration rate with
the MDRD formula is better (47.9 vs 39.5ml/mn/1.73m2, p=0.15), and there
is less inflammation. 89% patients in the transplantation group were under
anti-calcineurin and 50% under steroids at low dose. Platelet reactivity Index
a marker of the extent of P2Y12 inhibition was significantly higher in the
transplantation group vs controls (60.1% vs 51.2% p=0.014). By multivariate
analysis, high BMI and kidney transplantation were important predictors of
residual platelet reactivity under clopidogrel treatment. After adjustment on
eGFR with the MDRD formula, kidney transplantation remains an important
predictor of alter P2Y12 inhibition.
Conclusion: In kidney transplantation patients treated by clopidogrel,
impaired platelet inhibition exist, even after adjustment on estimated glomer-
ular filtration rate. The mechanisms by which immunosuppressive treatments
may alter clopidogrel pharmacodynamics requires further investigation
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Increased intracardiac VEGF and VWF levels revealed low grade
inflammatory process and progressive endothelial damage in patients
with AF
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Aims: Endothelial dysfunction seems to play a pivotal role in atrial fibril-
lation (AF). The purpose of this study was to investigate the relationship
between AF and vascular endothelial growth factor (VEGF) and to investigate
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the effect of different clinical forms of AF on plasma concentration of Von
Willebrand Factor (vWF) at different levels of circulatory tree, both intracar-
diac and extracardiac.
Methods and results: Peripheral (Pf), left atrial (LA), and coronary sinus
(CS) blood samples were obtained during cardiac catheterization from
52 patients with paroxysmal AF (PAF), 36 with persistent AF (PsAF), and 17
control subjects (Ct) with Wolff-Parkinson-White syndrome. Plasma levels of
VEGF and vWF were measured at the three sampled sites. Peripheral VEGF
levels were higher in both PAF and PsAF patients than in controls (P≤0.03).
Left atrial VEGF levels were higher in paroxysmal AF (P=0.05), but not in
persistent AF (P=0.32), compared with controls. Coronary sinus and pulmo-
nary vein VEGF levels did not differ significantly among groups. Compared
with Ct, patients with PAF had higher LA plasma levels of vWF (P=0.004),
but similar Pf and CS levels (both P>0.30). In contrast, patients with PsAF
had higher plasma concentrations of vWF in Pf (P=0.04), LA (P<0.001), and
CS (P=0.04) samples compared with Ct. Left atrial plasma concentrations of
vWF in patients with PsAF were also higher than in the PAF group (P=0.04).
Conclusion: This study suggests that inflammatory process in AF is of low
grade. The heart itself is the most likely source of high left atrial VEGF; how-
ever, this disorder appears to be a transient event in AF history. AF patients
presented significantly higher plasma concentrations of vWF. This study sug-
gests an association between the clinical evolution of AF and the progression
of endothelial dysfunction. Further studies will have to establish the exact
mechanisms that link endothelial dysfunction and stroke in the context of AF.
Abstract 0136 – Figure: vWF and VEGF plasma levels in the 3 study groups
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Effect of smoking on comparative efficacy of antithrombotic therapy
in patients with atrial fibrillation. A community based cohort study
Denis Angoulvant, Theodora Beja Angoulvant, Lauriane Pericart, Edouard
Simeon, Anne Brunet Bernard, Nicolas Clementy, Christophe Saint
Etienne, Dominique Babuty, Laurent Fauchier
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Smoking is incorporated in a simple score (SAMe-TT2R2) that can predict
poor INR control in patients with atrial fibrillation (AF) treated with vitamin K
antagonists (VKA). Moreover, the clinical benefit of clopidogrel in reducing myo-
cardial infarction and stroke in randomized clinical trials of antiplatelet drugs
(APD) was seen primarily in smokers, with little benefit in nonsmokers. We made
the hypothesis that active smoking may differently influence 1) the risk of stroke
and 2) the risk of bleeding in AF patients treated with VKA or with APD.
Methods: We examined the clinical course of 7.948 consecutive patients
with AF and/or atrial flutter seen between 2000-2010. The outcomes in
patients with active smoking were compared with those in other patients.
Results: Among 7.948 patients with AF (age 71±15 years), 1034 (13%) had
active smoking. APD was prescribed on an individual basis for 2761 patients
(35%) and VKA for 4534 (57%). During a follow-up of 929±1082 days, 631
strokes/thromboembolic events, 707 severe bleedings and 248 major BARC
bleedings were recorded. Smoking was not independently associated with a higher
risk of stroke in these AF patients (relative risk=0.94, 95% CI 0.75-1.18, p=0.62).
By contrast, after adjustment on age, CHADS2 score, HASBLED bleeding risk
score, VKA use and APD use, smoking was independently associated with a
worse prognosis for the risk of severe bleeding (relative risk=1.23, 95% CI 1,02-
1,50, p=0.03) and for the risk of major BARC bleeding (relative risk=1.40, 95%
CI 1.03-1.91, p=0.03). Smoking was independently associated with a higher risk
of bleeding in patients treated with VKA (relative risk= 1.32, 95% CI 1.04-1.66.
p=0.02) whilst this association did not reach significance in patients treated with
APD (relative risk=1.31, 95% CI 0.97-1.76. p=0.07).
Conclusion: In AF, there was a higher risk of bleeding in smokers, mainly
in those treated with VKA
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Effectiveness of switching Prasugrel’s ‘low responders’ to ticagrelor
after acute coronary syndrome
Clémence Bassez, Pierre Deharo, Mathieu Pankert, Jacques Quilici, Jean-
Louis Bonnet, Thomas Cuisset
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Aims: This study aimed to assess the effectiveness and safety of switching
from Prasugrel to Ticagrelor patients identified as Prasugrel low-responders
one month after ACS.
Methods and results: 540 patients admitted for ACS with coronary stent
implantation and discharged on Prasugrel 10mg were screened. Prasugrel
response was assessed one month after discharge using Platelet Reactivity
Index Vasodilatator Stimulated Phosphoprotein (PRI VASP). High on-Treat-
ment Platelet Reactivity (HTPR) was defined as VASP>50%. Patients with
HTPR were enrolled and switched to Ticagrelor 90 mg twice a day. They
were re-tested a month later. Primary endpoint was defined as: comparison of
degree of platelet inhibition and incidence of HTPR one month after switching
to Ticagrelor in patients with HTPR on Prasugrel therapy. The safety endpoint
was the incidence of bleedings under Ticagrelor as compared with Prasugrel
therapy, using the Bleeding Academic Research Consensus definition.
Between March 2010 and November 2013, 19 patients were defined as
HTPR on Prasugrel 10 mg one month after ACS, with a mean VASP of
59,3%. Among these patients, 14 were switched to Ticagrelor 180 mg daily
and, at one month, we observed a significant decrease in PRI VASP, with a
mean value at 19.6% (p<0.001). No patients remained HTPR and 4 patients
(28.4%) were identified as Very Low on-Treatment Platelet Reactivity
(VLTPR) (VASP<10%). No ischemic events were reported after switching,
while 3 patients (21%) suffered from bleeding complications (2 BARC1 and
1 BARC2 bleedings) during Ticagrelor therapy.
Conclusion: Switch to Ticagrelor in Prasugrel’s “low responders” patients is
an effective strategy, leading to an adequate platelet inhibition in a large majority
of patients. This biological tailored approach could be useful in preventing isch-
emic complications, in this specific high risk population, potentially increasing
bleeding risk. This hypothesis needs to be confirmed in large clinical studies.
Abstract 0230 – Figure
[ * : P<0.05 vs control:** : P<0.05 vs paroxysmal AF, using the unpaired t-test ]
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